Lenalid 5mg Tablets |Blueberry pharmaceuticals
lenalid 5mg
Lenalid 5mg contains Lenalidomide as an active substance which belongs to thalidomide analogue. Lenalid 5mg tablets contains some pharmacological activities like immuno modulatory, anti-neoplastic, & anti-angiogenesis. Lenalid 5mg is a prescription medicine; used under the supervision of medical oncologist. Lenalid 5mg is used by combining with dexamethasone.
Indication of Lenalid :
The most common indications of Lenalid 5mg are; Multiple myeloma: Lenalid 5mg should be used in combination with dexamethasone.
Myelodysplastic syndrome: Lenalid 5mg is used to treat this condition Mantle cell lymphoma: Lenalid 5mg dose is used for this condition, if patients are not responding to the Bortezomib treatment.
Mechanism of Lenalid :
Lenalid includes in the restraint of tumor rot factor alpha arrangement, which support the T-cells and causes lessening serum levels of cytokines vascular endothelial development factor and fundamental fibroblast development factor. Lenalid is additionally engaged with the preclusion of angiogenesis. Lenalidomide is additionally empowered G1 cell cycle capture and apoptosis of ruinous cells.
Dosage & Administration :
The usual prescribed dose of Lenalidomide in myelodysplastic syndromes is 10mg should be given as once a day.
For renal damaged patients;
In Patients with CrCl>60ml/min should not require dosage adjustment of Lenalidomide.
In Patients with CrCl 30 to 60ml/min, 5mg of Lenalidomideshould be given orally as once a day.
In Patient with CrCl <30ml/min, 2.5mg of Lenalidomideshould be administered orally as a once a day.
DOSAGE VARIATION
THROMBOCYTOPENIA
Drops to <50000/mcL, therapy should be interrupted. Back to > or equal to 50000/mcL, continue the Lenalidomideof 5mg/day.
NEUTROPENIA
Drops to <500/mcL, therapy should be postponed. Back to > or equal to 500/mcL, treatment should be continue to 5mg/day.
MULTIPLE MYELOMA
In this condition, Lenalidomideis concomitant with dexamethasone. The usual dose of Lenalidomideis 25mg should be administered as once daily on day 1 to 21. The dose of dexamethasone; 40mg of dexamethasone should be followed on day 1 to 4, 9 to 12 & 17 to 20 of each 28 day cycles. Patient with >75 years, 20mg of dexamethasone should be recommended on day 1, 8, 15, & 22.
MANTLE CELL LYMPHOMA
The advised dose of Lenalidomide for this condition is 25mg should be administered orally as once daily.
For renal damaged patients
Patient with CrCl 30 to 60ml/min, 10mg of Lenalidomideshould be administered as once daily.
Patient with CrCl<30ml/min, 15mg of Lenalidomideshould be used for q48hr.
Pediatrics
The potency & effectiveness of Lenalidomide has not been evaluated in pediatric patients with age of <18 years.
Drug interaction :
Lenalid 5mg tablets interaction with digoxin, causes increased concentration of digoxin causes increased risk of adverse effects related to digoxin.
Lenalid 5mg interaction with Erythropoietic agents, leads to produced increased risk of thrombosis. Counsel the patients before starting this combination treatment.
Lenalid 5mg interaction with warfarin, causes increased exposure of bleeding disorders. Monitor the INR value & prothrombin time.
Lenalid 5mg Warning :
The most common life threatening condition like: Embryo fetal damage, Hypersensitivity reactions, Venous & arterial thromboembolism, Blood clotting effects, Hematological disorders, For all these conditions, some supportive measures should be used and provide safety measures.
Contraindication :
Lenalid 5mg should be contraindicated to pregnancy period. Hypersensitivity reactions are produced due to patients are contraindicated to the Lenalid 5mg component.
Pregnancy :
Pregnancy category X Lenalid 5mg causes fetal damage leads to death Breast feeding should not be allowed..
Storage :
Lenalid 5mg capsules should be stored at 20°C to 25°C Protect the container from light Keep away from moisture & heat.
For More Information :
Call us : +91-97890 77748
Mail to : info@blueberrypharma.com
Domain : https://blueberrypharma.com/lenalid-5mg.php